MTOR and neoplasm: On the basis of the results present here, we speculate that tumor level and localization of PI3K/Akt/mTOR pathway activation before neo/adjuvant therapy can be used to predict which patients will benefit with a combination therapy with PI3K/mTOR inhibitors and which patients will not.